Aligos reports Q3 '26 progress, cash falls to $31.1M
Aligos Therapeutics reported cash of $31.1 million as of September 30, down from $77.8 million at year-end 2025. R&D decreased due to lower Phase 2 trial costs as the company initiates a Phase 1 study in China for its candidate ALG-170675.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed